In breast tumors, MDSCs exert their potent immunosuppressive functions through several pathways: (a) STAT3-NF-Κb-IDO, which is activated by tumor-derived IL-6 to activate STAT3 in MDSCs [171]. Here, STAT3 is linked to breast neoplasm.